Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Sprechen Sie mit dem Deal-Team
Transaktionen
Amot Investments Ltd. has issued bonds
Amot Investments Ltd. has raised funds to refinance the company for further development.
Mehr erfahrenPrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Mehr erfahrenCara Care wurde von Mahana Therapeutics übernommen
Mahana Therapeutics Inc., ein innovativer Anbieter von digitalen Gesundheitslösungen für chronische Erkrankungen, hat die Übernahme von Cara Care (HiDoc Technologies GmbH) abgeschlossen. Cara Care ist eine führende digitale Gesundheitsplattform und eine offizielle digitale Gesundheitsanwendung (DiGA) zur Verbesserung der Darmgesundheit. Diese Übernahme, die auch von den Investoren Lux Capital und Jazz Ventures Partners unterstützt wird, passt perfekt zur Expansionsstrategie von Mahana.
Mehr erfahren